Kyoto University · 의학
Misao Fujita 교수의 연구실은 재생의료 및 장기 이식 분야에서의 윤리적·법적 문제를 중심으로 연구를 진행하고 있습니다. 특히 생체은행, 유전자 치료, 배아 형성 등 재생의료 기술의 규제와 심의 체계에 대한 비판적 분석을 통해 환자의 안전과 연구의 투명성을 확보하고자 합니다. 또한, 기부자 결정 과정, 해외 이식 여행, 국내 규제 미비로 인한 임상적 위험 등 일본의 의료 체계적 문제를 다각도로 분석하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
This study examined the decision-making processes of donors in adult-to-adult living donor liver transplantation. Twenty-two donors were interviewed using a semi-structured format. Interview contents were transcribed verbatim and analyzed qualitatively using grounded theory. A decision-making model was developed consisting of 5 stages: (1) recognition, (2) digestion, (3) decision-making, (4) reinforcement, and (5) resolution. The second and the third stages described donors' experiences of "reac
Considering many patients travel to foreign countries to seek therapy, more research from non-English-speaking countries is needed.
Turner and colleagues recently argued that countries with unclear laws and regulations regarding stem cells, exosomes, and other regenerative medicine products should develop and enforce more comprehensive regulatory structures. We fully agree with this opinion and discuss that failure to do so may lead to troubling predicaments, such as the Japanese cases, where patients are at risk of serious complications or even death.
Against the backdrop of stalled progress on brain-dead organ transplants in Japan, patients continue to travel overseas, and for a long time, Japan has received international criticism for this. Th...
Based on our preliminary results, we recommended that a licensed physician perform a screening test to appropriately examine clear abnormalities. These recommendations were implemented by the SRPBS as guidelines for handling IFs in national research projects in Japan.
We outlined five studies regarding the quality of the review by committees based on the Act on the Safety of Regenerative Medicine. The findings raise serious concerns about the independence, integrity, and quality of reviews of therapeutic plans by these committees with inappropriately close relationships to medical institutions and companies.
The results that approximately half of the respondents answered that they would accept the creation of embryos with IVD-gametes, which has not been allowed in the current Japanese research guidelines, is astonishing.
<b>Background:</b> Multiple surveys of the general public and experts on human genome editing have been conducted. However, many focused only on editing in clinical applications, with few regarding its use for basic research. Given that genome editing for research purposes is indispensable for the realization of clinical genome editing, understanding lay attitudes toward genome editing in research, particularly using human embryos, which is likely to provoke ethical concerns, is helpful for futu
In Japan at present, the use of IVD-gametes that deviate from societal values regarding reproduction and family prescribed by the conventional marriage system is unlikely to be accepted. It is also unlikely to be accepted for non-treatment purposes in reproduction.
<b>Background:</b> The world's first gene-edited babies, reported by the Chinese scientist He Jiankui, prompted an outcry of criticism and concerns worldwide over the use of genome editing for reproductive purposes. Many countries and academic associations opposed to heritable genome editing (HGE) called for public discussion involving various stakeholders. To hold a discussion of this nature and form a consensus concerning HGE, we must understand under what conditions stakeholders consider HGE
This is the first study to determine the status of UCB provision to private banks by Japanese institutions handling childbirth. Future studies will need to examine in detail how institutions handling childbirth provide explanations to private bank users and UCB providers as well as how these institutions obtain consent.